Liraglutide and Rosuvastatin Interaction: What Patients and Prescribers Need to Know

How Common Is This Drug Combination?

Patients taking liraglutide for type 2 diabetes or obesity frequently carry cardiovascular risk factors that lead prescribers to add a statin. Rosuvastatin (Crestor and generics) is one of the most dispensed statins in the United States, with over 25 million prescriptions filled annually according to IQVIA data cited by the CDC. Liraglutide (Victoza for type 2 diabetes, Saxenda for weight management) is itself prescribed to millions of patients with overlapping metabolic risk. The co-prescription rate is high enough that every clinician managing cardiometabolic disease needs a working understanding of how these two agents interact.

Why This Pairing Deserves a Dedicated Review

Most statin interaction reviews focus on CYP3A4 inhibitors and statin myopathy. Rosuvastatin is not metabolized by CYP3A4 to a meaningful degree, so the usual CYP warnings do not apply here [1]. Liraglutide, a GLP-1 receptor agonist, affects drug absorption through a different pathway entirely: slowing of gastric emptying. That mechanism is frequently overlooked in standard drug-interaction checkers, which can give clinicians false reassurance about the combination.

Pharmacokinetics of Each Drug

Liraglutide

Liraglutide is a 97% homologous analog of human GLP-1, administered by subcutaneous injection. It is not absorbed through the GI tract and does not directly interact with hepatic cytochrome P450 enzymes or drug transporters [2]. Its half-life is approximately 13 hours, supporting once-daily dosing. The FDA-approved label for Victoza states: "Liraglutide causes a delay in gastric emptying, thereby having the potential to impact the absorption of concomitantly administered oral medications" [2].

Rosuvastatin

Rosuvastatin is a synthetic, fully water-soluble HMG-CoA reductase inhibitor. Unlike simvastatin or atorvastatin, it undergoes minimal CYP2C9 metabolism (approximately 10%) and negligible CYP3A4 metabolism [1]. Its hepatic uptake depends heavily on the organic anion transporting polypeptides OATP1B1 and OATP1B3, encoded by the SLCO1B1 and SLCO1B3 genes. Rosuvastatin is also a substrate of the breast cancer resistance protein (BCRP) efflux transporter [3]. Bioavailability is approximately 20%, and peak plasma concentration (Cmax) is reached at 3 to 5 hours after oral dosing [1].

The Core Interaction Mechanism

Gastric Emptying Delay

The primary pharmacokinetic interaction between liraglutide and rosuvastatin is driven by liraglutide's well-documented delay of gastric emptying. GLP-1 receptors in the enteric nervous system and the pylorus slow the rate at which gastric contents pass into the duodenum [4]. For drugs with narrow absorption windows or steep concentration-response relationships, this delay matters clinically.

A dedicated drug-interaction study published in the liraglutide regulatory package examined liraglutide 1.8 mg co-administered with rosuvastatin 40 mg. Rosuvastatin Cmax fell by approximately 10% and time to maximum concentration (Tmax) increased by 1.1 hours [2]. The area under the curve (AUC), which reflects total drug exposure, was essentially unchanged. Because rosuvastatin's LDL-lowering effect correlates more closely with AUC than Cmax, the modest Cmax reduction is unlikely to reduce efficacy at steady state.

OATP Transporter Considerations

Liraglutide does not inhibit OATP1B1 or OATP1B3 at clinically relevant concentrations. The interaction study data support this: an unchanged AUC is inconsistent with meaningful transporter inhibition, which would increase rosuvastatin exposure rather than decrease it [3]. Clinicians should be aware that other co-medications, such as gemfibrozil or cyclosporine, can potently inhibit OATP1B1 and dramatically raise rosuvastatin exposure, but liraglutide is not in that category [1].

Pharmacodynamic Overlap: Myopathy Risk

Both liraglutide and rosuvastatin have been associated, independently, with muscle-related adverse effects. Statin-associated muscle symptoms (SAMS) affect an estimated 5 to 10% of statin users in clinical practice, though the STOMP trial (N=420) found myalgia rates of 9.4% with atorvastatin 80 mg vs. 4.6% placebo over 6 months [5]. Rosuvastatin carries a class warning for myopathy and rhabdomyolysis, with risk rising at doses above 20 mg per day and in patients with hypothyroidism, renal impairment, or Asian ancestry [1].

GLP-1 receptor agonists including liraglutide have been associated with musculoskeletal adverse events in post-marketing surveillance, though a direct mechanistic causal link to myopathy has not been established [4]. The pharmacodynamic interaction is therefore additive in theory rather than synergistic, and the absolute risk increase from combining the two agents remains small.

Severity Classification

The table below summarizes how this interaction maps to standard DDI severity frameworks used by clinical pharmacologists.

| Dimension | Finding | Severity | |---|---|---| | Rosuvastatin Cmax change | -10% with liraglutide 1.8 mg | Minor | | Rosuvastatin AUC change | No significant change | Negligible | | Tmax shift | +1.1 hours | Minor | | Myopathy risk (additive PD) | Small absolute increase | Low-moderate | | Overall interaction classification | No contraindication; monitoring appropriate | Category C (monitor) |

A "Category C" interaction in most DDI databases (including Lexicomp and Micromedex) means the combination is acceptable but warrants clinical monitoring. It does not mean the two drugs cannot be used together [6].

Clinical Evidence From Key Trials

LEADER Trial and Lipid Co-medication

The LEADER trial (N=9,340) evaluated liraglutide 1.8 mg daily vs. Placebo in patients with type 2 diabetes and high cardiovascular risk over a median follow-up of 3.8 years [7]. Approximately 72% of participants were on statin therapy at baseline, and rosuvastatin was among the most commonly used agents. No excess signal for statin-related adverse events (myopathy, rhabdomyolysis, hepatotoxicity) was observed in the liraglutide arm compared with placebo [7]. The LEADER results provide the most strong real-world evidence that liraglutide plus a statin, including rosuvastatin, is safe in a large cardiometabolic population.

SCALE Obesity and Prediabetes Trial

The SCALE trial (N=3,731) studied liraglutide 3.0 mg (Saxenda) for weight management over 56 weeks [8]. Statin use was prevalent among participants. Musculoskeletal adverse events were reported at similar frequencies in liraglutide and placebo arms, consistent with the absence of a clinically meaningful additive myopathy signal [8].

Rosuvastatin Cardiovascular Outcomes: JUPITER

The JUPITER trial (N=17,802) established rosuvastatin 20 mg as effective for primary cardiovascular prevention in patients with elevated high-sensitivity CRP [9]. Patients in JUPITER with metabolic syndrome, a population highly likely to overlap with liraglutide users, did not show excess muscle toxicity. The trial offers useful context for what rosuvastatin myopathy rates look like in a high-cardiovascular-risk population without GLP-1 co-administration.

Dose Adjustment Guidance

Rosuvastatin Dosing With Liraglutide

Routine dose adjustment of rosuvastatin is not recommended when adding liraglutide. The 10% Cmax reduction is clinically trivial for a drug whose efficacy is AUC-driven. The FDA label for rosuvastatin (Crestor) does not list GLP-1 receptor agonists among drugs requiring dose modification [1].

If a patient's LDL-C goal is not met after starting liraglutide, the cause is unlikely to be the pharmacokinetic interaction. Dietary adherence, statin compliance, and underlying lipid genetics are far more probable explanations and should be assessed first.

Liraglutide Titration Is Unchanged

Starting liraglutide at 0.6 mg daily and titrating by 0.6 mg increments weekly, as specified in the Victoza label, does not need modification based on concurrent rosuvastatin use [2]. Rosuvastatin does not alter GLP-1 receptor signaling or liraglutide pharmacokinetics.

When Timing of Administration Matters

For most patients, simultaneous administration of rosuvastatin and liraglutide injection poses no practical concern. However, if a patient is taking rosuvastatin for a condition where achieving high peak concentrations is thought to matter (for example, some providers time statin dosing around meals for patient adherence), separating rosuvastatin from the period of maximal gastric-emptying inhibition, roughly 2 to 3 hours after liraglutide injection, may modestly normalize Cmax [4]. This is a pragmatic suggestion, not a label requirement.

Monitoring Recommendations

Lipid Panel Surveillance

Patients starting or escalating liraglutide while on rosuvastatin should have a fasting lipid panel checked 6 to 12 weeks after any dose change, consistent with ACC/AHA lipid guideline recommendations for statin monitoring [10]. Liraglutide independently reduces triglycerides and may modestly lower LDL in some patients, so lipid targets may actually be easier to reach on the combination [7].

Creatine Kinase and Muscle Symptoms

Routine CK measurement before starting rosuvastatin is no longer universally recommended by the ACC/AHA 2018 cholesterol guidelines, which state: "It is reasonable to measure CK in individuals with muscle symptoms" [10]. The same standard applies here. There is no indication to check CK at baseline solely because liraglutide is being co-prescribed. CK should be checked if a patient reports myalgia, muscle weakness, or dark urine while on the combination.

Renal Function

Rosuvastatin exposure increases in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), requiring a maximum dose of 10 mg daily in that population [1]. Liraglutide can cause nausea, vomiting, and reduced oral intake, which may transiently affect renal perfusion in volume-sensitive patients. Checking a basic metabolic panel when initiating liraglutide in patients already on rosuvastatin is reasonable clinical practice, particularly in older adults or those with pre-existing chronic kidney disease.

Patient Counseling Points

What to Tell Patients Taking Both Medications

Patients often search for information about drug interactions themselves and may arrive at appointments concerned. A clear, reassuring, and accurate explanation reduces unnecessary medication discontinuation. Key messages include:

• The combination is used safely in thousands of patients with diabetes and cardiovascular disease, as shown in the LEADER trial [7].
• Rosuvastatin still works at the same dose. The liraglutide-related reduction in peak statin levels does not meaningfully reduce LDL-lowering effectiveness.
• Report any unexplained muscle pain, weakness, or brown-colored urine promptly. These symptoms are rare but warrant a CK test.
• Take rosuvastatin at a consistent time each day. If adherence is better in the evening, evening dosing is fine and avoids the window of maximal gastric-emptying inhibition after the morning liraglutide injection.

Recognizing Symptoms That Require Medical Attention

The most serious statin-related adverse effect is rhabdomyolysis, defined by CK elevation greater than 10 times the upper limit of normal with renal injury. Rhabdomyolysis is rare with rosuvastatin monotherapy, with an estimated incidence of less than 1 per 10,000 patient-years [1]. The additive risk from liraglutide co-administration is not quantified in the current literature, but there is no mechanistic basis to expect a substantial increase.

Patients should seek medical evaluation if they develop:

• Severe or progressive muscle pain lasting more than a few days
• Muscle weakness affecting daily activities
• Dark or cola-colored urine
• Fever with muscle symptoms

Special Populations

Patients of Asian Ancestry

The rosuvastatin label includes a specific warning that patients of Asian ancestry, particularly those of Chinese, Japanese, Korean, Vietnamese, or South Asian descent, have roughly twice the plasma exposure to rosuvastatin compared to Caucasian patients [1]. The FDA label recommends starting at 5 mg daily in these patients. This recommendation is independent of liraglutide co-administration but is worth reiterating because this population carries substantial type 2 diabetes prevalence and is likely to be prescribed both agents.

Patients With Hypothyroidism

Hypothyroidism independently increases statin myopathy risk. Patients on liraglutide for weight management often carry undiagnosed or undertreated hypothyroidism. A TSH check before escalating rosuvastatin in liraglutide-treated patients with weight management failure may identify a modifiable myopathy risk factor [5].

Older Adults (Age 65 and Over)

Both liraglutide-induced volume depletion risk and age-related decline in renal rosuvastatin clearance converge in older patients. The ACC/AHA 2018 guideline flags age as an "additional factor" that may influence statin intensity decisions [10]. Prescribers should favor rosuvastatin doses of 10 to 20 mg rather than 40 mg in patients over 75 who are also on liraglutide, unless a compelling cardiovascular indication exists.

Comparison With Other GLP-1 Agonists

Does This Interaction Apply to Semaglutide or Tirzepatide?

Semaglutide (Ozempic, Wegovy) also delays gastric emptying and carries the same pharmacokinetic interaction signal with orally administered drugs as liraglutide. A dedicated interaction study with rosuvastatin has not been published for semaglutide to the same level of detail as the liraglutide data, but the mechanism is shared [4]. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist with a similar gastric-emptying effect profile. Prescribers transitioning patients between these agents should not assume the interaction profile changes substantially. The same Cmax reduction, AUC stability, and clinical acceptability framework applies.

Why Rosuvastatin Is Different From Atorvastatin in This Context

Atorvastatin is a CYP3A4 substrate, making it susceptible to a wider range of drug interactions than rosuvastatin. The liraglutide-atorvastatin pharmacokinetic interaction is primarily the same gastric-emptying delay mechanism described here. Neither statin requires dose adjustment due to GLP-1 co-administration, but rosuvastatin's reliance on OATP transporters rather than CYP enzymes makes its overall interaction profile different when other co-medications are added to the regimen. Clinicians managing a patient on liraglutide, rosuvastatin, and a third agent (such as cyclosporine or gemfibrozil) should re-evaluate rosuvastatin dosing based on the OATP inhibitor's effect, not liraglutide's [1].

Summary of Key Clinical Actions

The following checklist consolidates the monitoring and prescribing actions supported by the evidence reviewed above.

1. Continue rosuvastatin at its current dose when initiating liraglutide. No dose reduction or increase is warranted based on the interaction alone.
2. Check a fasting lipid panel 6 to 12 weeks after any liraglutide dose change, per ACC/AHA lipid monitoring guidance [10].
3. Obtain CK only if the patient reports muscle pain, weakness, or dark urine. Routine pre-treatment CK is not required by current guidelines.
4. Check basic metabolic panel at liraglutide initiation in patients over 65, those with chronic kidney disease (eGFR <60 mL/min/1.73 m²), or those on concurrent diuretics.
5. Start rosuvastatin at 5 mg daily in patients of Asian ancestry regardless of liraglutide co-administration [1].
6. If the patient is also taking gemfibrozil or cyclosporine, cap rosuvastatin at 10 mg daily due to OATP inhibition, irrespective of the liraglutide interaction [1].